Journals club - HPV vaccine

Curriculum statement 5. Healthy people: promoting health and preventing disease.

Key trials

  • Cervarix is adjuvanted with aluminium hydroxide with monophosphoryl lipid A (ASO4). This has been used in a hepatitis B vaccine, where it was shown to generate a stronger and longer-lasting immune response than a vaccine containing aluminium hydroxide alone (Cancer Immunol Immunother 2008; 57: 443-51).
  • One study showed 90.4 per cent efficacy against cervical intraepithelial neoplasia 2 and 3 associated with HPV16 or HPV18 (Lancet 2007; 369: 2,161-70).
  • A pilot study achieved a 70.6 per cent uptake for the first dose of vaccine, with a drop of only 2.1 per cent for the second dose (BMJ 2008; 336: 1,056-8).

However, the uptake of the vaccine in this study was highest in girls from affluent, white backgrounds, who have the lowest incidence of cervical cancer.

  • The HPV vaccine does appear to be associated with a greater risk (2.6 per 100,000 doses) of anaphylaxis than other immunisations (CMAJ 2008; 179: 525-33).

Evidence base

  • The Royal College of Obstetricians and Gynaecologists has welcomed the government's implementation of the HPV vaccination programme in teenage girls.
  • The DoH accepted advice from the Joint Committee on Vaccination and Immunisation regarding the HPV vaccine.
  • The introduction of the HPV vaccine into the National Immunisation Programme has been detailed in a CMO publication (see


  • The DoH has chosen Cervarix HPV vaccine for the national immunisation campaign.
  • For optimal protection, the vaccine needs to be given before the onset of sexual activity.
  • The routine vaccination of girls aged 12-13 years of age started in September 2008.
  • The choice of vaccine has been criticised by many experts because it means that the potential for vaccination against genital warts is lost.
  • The DoH has stated it is not cost-effective for boys to be vaccinated.
  • Vaccinated women will still need to have regular cervical smear tests because:
    vaccination will take several years to reduce the incidence of cervical cancer;
    vaccination does not offer protection against all HPV types;
    unvaccinated women will not be protected.

Contributed by Dr Louise Newson, a GP in the West Midlands

HPV points

  • Persistent HPV infection can lead to cervical cancer.
  • HPV infection affects approximately 1 in 5 women.
  • Cervarix is the vaccine of choice for the HPV vaccination programme in the UK.
  • Data on long-term immunity with the vaccine is not yet available.
  • Poor uptake of the vaccine is a concern.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

Woman holding face in pain

Should GPs treat patients presenting with dental problems?

The MDU's Dr Kathryn Leask considers what GPs should do if a patient presents with...

Conservative Party leadership candidate and foreign secretary Liz Truss

Liz Truss vows to resolve GP pension tax crisis if she becomes prime minister

Liz Truss has affirmed her commitment to resolving the GP pensions crisis but has...

Baby receiving a vaccine in their thigh

JCVI advises changes to routine childhood and HPV immunisation schedules

The Joint Committee on Vaccination and Immunisation (JCVI) has recommended a change...

GP consultation

General practice delivering 'up to double the appointments it is paid for'

General practice in England may be delivering as many as double the number of appointments...

Sign outside BMA House

GP suicide sparks calls for measures to protect doctors from spiralling workloads

The government and policymakers must do more to safeguard doctors and NHS staff from...

Talking General Practice logo

Podcast: Living with long COVID

In August we’re bringing you some of the best interviews from series one of the podcast....